SCHEMBL1472300

SCHEMBL1472300

FC1CCC(F)(F)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472249 0.80
SCHEMBL16256358 0.72
4,4-Difluoro-Piperidinium SCHEMBL7446490 0.72
SCHEMBL10404 0.71
SCHEMBL5904396 0.71
SCHEMBL697502 0.69
SCHEMBL23734652 0.69
SCHEMBL17110878 0.69
SCHEMBL23169287 0.69
SCHEMBL2406454 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3249682-B1 SUBSTRATE TREATING METHOD SCREEN HOLDINGS CO LTD (JP) 2022-08-24 EP claimed
US-10153181-B2 Substrate treating apparatus and substrate treating method SCREEN Holdings Co., Ltd. (JP) 2018-12-11 US claimed
US-10040759-B2 Substituted azetidinyl compounds as GlyT1 inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2018-08-07 US claimed
US-20170345683-A1 SUBSTRATE TREATING APPARATUS AND SUBSTRATE TREATING METHOD SCREEN Holdings Co., Ltd. (JP) 2017-11-30 US claimed
EP-3249682-A1 SUBSTRATE TREATING APPARATUS AND SUBSTRATE TREATING METHOD SCREEN Holdings Co., Ltd. (JP) 2017-11-29 EP claimed
US-20170334846-A1 SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-11-23 US claimed
EP-3215500-A1 SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS Dart NeuroScience (Cayman) Ltd. (KY) 2017-09-13 EP claimed
US-9708334-B2 Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-07-18 US claimed
EP-3134406-A1 SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2017-03-01 EP claimed
US-20170044167-A1 SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS DART NEUROSCIENCE LLC 2017-02-16 US claimed
WO-2016073420-A1 SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS DART NEUROSCIENCE, LLC (US) 2016-05-12 WO claimed
WO-2015164520-A1 SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS DART NEUROSCIENCE, LLC (US) 2015-10-29 WO claimed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
US-11574821-B2 Substrate treating method, substrate treating liquid and substrate treating apparatus SCREEN Holdings Co., Ltd. 2023-02-07 US disclosed
EP-3249682-B1 SUBSTRATE TREATING METHOD SCREEN HOLDINGS CO LTD (JP) 2022-08-24 EP disclosed
US-20220189762-A1 SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING APPARATUS SCREEN Holdings Co., Ltd. (JP) 2022-06-16 US disclosed
EP-2905279-A1 IMIDAZOLE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2015-08-12 EP disclosed
US-20150133400-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Opna Bio SA (CH) 2015-05-14 US disclosed
US-20110068086-A1 PLASMA ETCHING METHOD ZEON CORPORATION (JP) 2011-03-24 US disclosed
CN-101983417-A Plasma etching method ZEON CORP 2011-03-02 CN disclosed